Skip to main content
European Commission logo print header
Content archived on 2022-12-23

Development and Evaluation of Immunological and Virological Progression Markers to be Used for Monitoring of Therapy in HIV Infection (HU)

Objective



Study of Neutralizing and Enhancing Antibodies Measured in
Complement-Restored Serum Samples a5 Predictive Markers of progression of the HIV Disease ànd Monitoring of Therapy in HIV lnfection.
The authors would like to study if measurement of complement-dependent HIV neutralizing and enhancing antibodies which were found to be a novel predictive marker for AIDS development by their group recently can be applied for monitoring of therapy in HIV infection as Well. They plan to perform three series of experiments in order to check this assumption. 1) Longitudinal measurement of complement dependent neutralizing and enhancing antibodies in patients treated with AZT and/or ddc. They would like to te5t 100 samples from 20 patients for the titre of complement-dependent neutralizing and enhancing antibodies bY using the methods described in their previous papers; 2) participation in new approaches for therapy of HIV disease. In collaboration With a German group they would like to longitudinally test for these antibodies patients treated With N-acetylcystein. They are also ready to test samples from other groups involved in the EC-CA who perform treatment with different cytokines, such as IL-20r IL-12 or cytokine inhibitors; 3) Comparative study of the predictive value of the complement-dependent enhancement bY measuring complement dependent enhancing antibodies on the one hand and Iga and Igg class anti Fab and anti-F(ab')2 antibodies on the other in parallel in longitudinal samples from untreated early, asymptomatic and AZT treated symptomatic patients (total: 100 samples). This project will be performed in collaboration with a group from Heidelberg: the preliminary results are promising. If the additional Proposal is successfully finished, it can contribute to the success of the original programme bv providina a novel marker for monitoring of HIV therapy. Scientific aualification of the proposer is satisfactory: they have regular publications in international journals.

Call for proposal

Data not available

Coordinator

Centraal Laboratorium van het Nederlandse Rode Kruis - Bloedtransfusiedienst
EU contribution
No data
Address
125,Plesmanlaan
1066 CX Amsterdam
Netherlands

See on map

Total cost
No data

Participants (1)